{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:26:59Z","timestamp":1762100819692},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T00:00:00Z","timestamp":1213056000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuromol Med"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s12017-008-8035-0","type":"journal-article","created":{"date-parts":[[2008,6,9]],"date-time":"2008-06-09T14:05:00Z","timestamp":1213020300000},"page":"195-207","source":"Crossref","is-referenced-by-count":24,"title":["Maximizing the Potential of Plasma Amyloid-Beta as a Diagnostic Biomarker for Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"10","author":[{"given":"Esther S.","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stina M.","family":"Fangmark Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,10]]},"reference":[{"key":"8035_CR1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., et al. (1999). Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset\u00a0alzheimer disease and stability during the course of disease. Archives of Neurology, 56, 673\u2013680.","journal-title":"Archives of Neurology"},{"key":"8035_CR2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000086429","volume":"2","author":"A Asami-Odaka","year":"2005","unstructured":"Asami-Odaka, A., Obayashi-Adachi, Y., Matsumoto, Y., Takahashi, H., Fukumoto, H., Horiguchi, T., et al. (2005). Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer\u2019s disease. Neurodegeneration Diseases, 2, 36\u201343.","journal-title":"Neurodegener Dis"},{"key":"8035_CR3","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1212\/01.WNL.0000137040.64252.ED","volume":"63","author":"A Assini","year":"2004","unstructured":"Assini, A., Cammarata, S., Vitali, A., Colucci, M., Giliberto, L., Borghi, R., et al. (2004). Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology, 63, 828\u2013831.","journal-title":"Neurology"},{"key":"8035_CR4","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.wnl.0000256043.50901.e3","volume":"68","author":"RJ Bateman","year":"2007","unstructured":"Bateman, R. J., Wen, G., Morris, J. C., & Holtzman, D. M. (2007). Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology, 68, 666\u2013669.","journal-title":"Neurology"},{"key":"8035_CR5","first-page":"39","volume":"61","author":"DJ Begley","year":"2003","unstructured":"Begley, D. J., & Brightman, M. W. (2003). Structural and functional aspects of the blood\u2013brain barrier. Progress in Drug Research, 61, 39\u201378.","journal-title":"Progress in Drug Research"},{"key":"8035_CR6","doi-asserted-by":"crossref","first-page":"32916","DOI":"10.1074\/jbc.271.51.32916","volume":"271","author":"AL Biere","year":"1996","unstructured":"Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996). Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. Journal of Biological Chemistry, 271, 32916\u201332922.","journal-title":"Journal of Biological Chemistry"},{"key":"8035_CR7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0306-4522(99)00458-3","volume":"95","author":"AA Boyt","year":"2000","unstructured":"Boyt, A. A., Taddei, T. K., Hallmayer, J., Helmerhorst, E., Gandy, S. E., Craft, S., et al. (2000). The effect of insulin and glucose on the plasma concentration of Alzheimer\u2019s amyloid precursor protein. Neuroscience, 95, 727\u2013734.","journal-title":"Neuroscience"},{"key":"8035_CR8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0304-3940(89)90479-5","volume":"103","author":"H Braak","year":"1989","unstructured":"Braak, H., Braak, E., Ohm, T., & Bohl, J. (1989). Alzheimer\u2019s disease: Mismatch between amyloid plaques and neuritic plaques. Neuroscience Letters, 103, 24\u201328.","journal-title":"Neuroscience Letters"},{"key":"8035_CR9","doi-asserted-by":"crossref","first-page":"15977","DOI":"10.1016\/S0021-9258(18)55493-4","volume":"265","author":"AI Bush","year":"1990","unstructured":"Bush, A. I., Martins, R. N., Rumble, B., Moir, R., Fuller, S., Milward, E., et al. (1990). The amyloid precursor protein of Alzheimer\u2019s disease is released by human platelets. Journal of Biological Chemistry, 265, 15977\u201315983.","journal-title":"Journal of Biological Chemistry"},{"key":"8035_CR10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/bbrc.1999.0623","volume":"258","author":"VP Chauhan","year":"1999","unstructured":"Chauhan, V. P., Ray, I., Chauhan, A., & Wisniewski, H. M. (1999). Binding of gelsolin, a secretory protein, to amyloid beta-protein. Biochemical and Biophysical Research Communications, 258, 241\u2013246.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"8035_CR11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/bbrc.1995.2103","volume":"213","author":"M Chen","year":"1995","unstructured":"Chen, M., Inestrosa, N. C., Ross, G. S., & Fernandez, H. L. (1995). Platelets are the primary source of amyloid beta-peptide in human blood. Biochemical and Biophysical Research Communications, 213, 96\u2013103.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"8035_CR12","doi-asserted-by":"crossref","first-page":"22987","DOI":"10.1074\/jbc.272.37.22987","volume":"272","author":"LP Choo-Smith","year":"1997","unstructured":"Choo-Smith, L. P., Garzon-Rodriguez, W., Glabe, C. G., & Surewicz, W. K. (1997). Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. Journal of Biological Chemistry, 272, 22987\u201322990.","journal-title":"Journal of Biological Chemistry"},{"key":"8035_CR13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0306-4530(02)00087-2","volume":"28","author":"S Craft","year":"2003","unstructured":"Craft, S., Asthana, S., Cook, D. G., Baker, L. D., Cherrier, M., Purganan, K., et al. (2003). Insulin dose\u2013response effects on memory and plasma amyloid precursor protein in Alzheimer\u2019s disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology, 28, 809\u2013822.","journal-title":"Psychoneuroendocrinology"},{"key":"8035_CR14","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1212\/WNL.38.11.1682","volume":"38","author":"H Crystal","year":"1988","unstructured":"Crystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., et al. (1988). Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer\u2019s disease. Neurology, 38, 1682\u20131687.","journal-title":"Neurology"},{"key":"8035_CR15","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000295996.54210.69","volume":"69","author":"JL Cummings","year":"2007","unstructured":"Cummings, J. L., Doody, R., & Clark, C. (2007). Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology, 69, 1622\u20131634.","journal-title":"Neurology"},{"key":"8035_CR16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.nbd.2006.03.013","volume":"23","author":"K DaSilva","year":"2006","unstructured":"DaSilva, K., Brown, M. E., Westaway, D., & McLaurin, J. (2006). Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiology of Disease, 23, 433\u2013444.","journal-title":"Neurobiology of Disease"},{"key":"8035_CR17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2796.2004.01381.x","volume":"256","author":"MJ Leon de","year":"2004","unstructured":"de Leon, M. J., DeSanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., et al. (2004). MRI and CSF studies in the early diagnosis of Alzheimer\u2019s disease. Journal of Internal Medicine, 256, 205\u2013223.","journal-title":"Journal of Internal Medicine"},{"key":"8035_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0896-6273(03)00205-8","volume":"38","author":"B Strooper De","year":"2003","unstructured":"De Strooper, B. (2003). Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron, 38, 9\u201312.","journal-title":"Neuron"},{"key":"8035_CR19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm890","volume":"9","author":"R Deane","year":"2003","unstructured":"Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., et al. (2003). RAGE mediates amyloid-beta peptide transport across the blood\u2013brain barrier and accumulation in brain. Nature Medicine, 9, 907\u2013913.","journal-title":"Nature Medicine"},{"key":"8035_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuron.2004.07.017","volume":"43","author":"R Deane","year":"2004","unstructured":"Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., et al. (2004). LRP\/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron, 43, 333\u2013344.","journal-title":"Neuron"},{"key":"8035_CR21","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., & Holtzman, D. M. (2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer\u2019s disease. Proceedings of the National Academy of Sciences of the United States of America, 98, 8850\u20138855.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"8035_CR22","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","volume":"295","author":"RB DeMattos","year":"2002","unstructured":"DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002a). Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer\u2019s disease. Science, 295, 2264\u20132267.","journal-title":"Science"},{"key":"8035_CR23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1471-4159.2002.00889.x","volume":"81","author":"RB DeMattos","year":"2002","unstructured":"DeMattos, R. B., Bales, K. R., Parsadanian, M., O\u2019Dell, M. A., Foss, E. M., Paul, S. M., et al. (2002b). Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer\u2019s disease. Journal of Neurochemistry, 81, 229\u2013236.","journal-title":"Journal of Neurochemistry"},{"key":"8035_CR24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., et al. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model. Nature Neuroscience, 5, 452\u2013457.","journal-title":"Nature Neuroscience"},{"key":"8035_CR26","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","volume":"75","author":"RC Dodel","year":"2004","unstructured":"Dodel, R. C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., et al. (2004). Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer\u2019s disease. Journal of Neurology, Neurosurgery and Psychiatry, 75, 1472\u20131474.","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"8035_CR25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","volume":"52","author":"R Dodel","year":"2002","unstructured":"Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., et al. (2002). Human antibodies against amyloid beta peptide: A potential treatment for Alzheimer\u2019s disease. Annals of Neurology, 52, 253\u2013256.","journal-title":"Annals of Neurology"},{"key":"8035_CR27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund, H., Sehlin, D., Johansson, A. S., Nilsson, L. N., Gellerfors, P., Paulie, S., et al. (2007). Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. Journal of Neurochemistry, 103, 334\u2013345.","journal-title":"Journal of Neurochemistry"},{"key":"8035_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/gepi.1015","volume":"21","author":"N Ertekin-Taner","year":"2001","unstructured":"Ertekin-Taner, N., Graff-Radford, N., Younkin, L. H., Eckman, C., Adamson, J., Schaid, D. J., et al. (2001). Heritability of plasma amyloid beta in typical late-onset\u00a0alzheimer\u2019s disease pedigrees. Genetic Epidemiology, 21, 19\u201330.","journal-title":"Genetic Epidemiology"},{"key":"8035_CR29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1212\/01.wnl.0000278386.00035.21","volume":"70","author":"N Ertekin-Taner","year":"2008","unstructured":"Ertekin-Taner, N., Younkin, L. H., Yager, D. M., Parfitt, F., Baker, M. C., Asthana, S., et al. (2008). Plasma amyloid beta protein is elevated in late-onset\u00a0alzheimer disease families. Neurology, 70, 596\u2013606.","journal-title":"Neurology"},{"key":"8035_CR30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/jnr.10745","volume":"74","author":"G Evin","year":"2003","unstructured":"Evin, G., Zhu, A., Holsinger, R. M., Masters, C. L., & Li, Q. X. (2003). Proteolytic processing of the Alzheimer\u2019s disease amyloid precursor protein in brain and platelets. Journal of Neuroscience Research, 74, 386\u2013392.","journal-title":"Journal of Neuroscience Research"},{"key":"8035_CR31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S. Y., Dence, C. S., Shah, A. R., et al. (2006). Inverse relation between in\u00a0vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Annals of Neurology, 59, 512\u2013519.","journal-title":"Annals of Neurology"},{"key":"8035_CR32","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/archneur.62.10.noc50112","volume":"62","author":"MA Fishel","year":"2005","unstructured":"Fishel, M. A., Watson, G. S., Montine, T. J., Wang, Q., Green, P. S., Kulstad, J. J., et al. (2005). Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Archives of Neurology, 62, 1539\u20131544.","journal-title":"Archives of Neurology"},{"key":"8035_CR33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/NEN.0b013e31803d3ae4","volume":"66","author":"SH Freeman","year":"2007","unstructured":"Freeman, S. H., Raju, S., Hyman, B. T., Frosch, M. P., & Irizarry, M. C. (2007). Plasma Abeta levels do not reflect brain Abeta levels. Journal of Neuropathology and Experimental Neurology, 66, 264\u2013271.","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"8035_CR34","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneur.60.7.958","volume":"60","author":"H Fukumoto","year":"2003","unstructured":"Fukumoto, H., Tennis, M., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003). Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Archives of Neurology, 60, 958\u2013964.","journal-title":"Archives of Neurology"},{"key":"8035_CR35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/JAD-2005-8403","volume":"8","author":"D Galasko","year":"2005","unstructured":"Galasko, D. (2005). Biomarkers for Alzheimer\u2019s disease\u2014clinical needs and application. Journal of Alzheimers Disease, 8, 339\u2013346.","journal-title":"J Alzheimers Dis"},{"key":"8035_CR36","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1523\/JNEUROSCI.21-08-02561.2001","volume":"21","author":"L Gasparini","year":"2001","unstructured":"Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., et al. (2001). Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. Journal of Neuroscience, 21, 2561\u20132570.","journal-title":"Journal of Neuroscience"},{"key":"8035_CR37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2007.09.023","volume":"427","author":"V Giedraitis","year":"2007","unstructured":"Giedraitis, V., Sundelof, J., Irizarry, M. C., Garevik, N., Hyman, B. T., Wahlund, L. O., et al. (2007). The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer\u2019s disease. Neuroscience Letters, 427, 127\u2013131.","journal-title":"Neuroscience Letters"},{"key":"8035_CR38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature, 349, 704\u2013706.","journal-title":"Nature"},{"key":"8035_CR39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0925-4439(00)00043-0","volume":"1502","author":"TE Golde","year":"2000","unstructured":"Golde, T. E., Eckman, C. B., & Younkin, S. G. (2000). Biochemical detection of Abeta isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer\u2019s disease. Biochimica et Biophysica Acta, 1502, 172\u2013187.","journal-title":"Biochimica et Biophysica Acta"},{"key":"8035_CR40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archneur.64.3.354","volume":"64","author":"NR Graff-Radford","year":"2007","unstructured":"Graff-Radford, N. R., Crook, J. E., Lucas, J., Boeve, B. F., Knopman, D. S., Ivnik, R. J., et al. (2007). Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Archives of Neurology, 64, 354\u2013362.","journal-title":"Archives of Neurology"},{"key":"8035_CR41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/WNR.0b013e3280148e76","volume":"18","author":"AJ Gray","year":"2007","unstructured":"Gray, A. J., Sakaguchi, G., Shiratori, C., Becker, A. G., LaFrancois, J., Aisen, P. S., et al. (2007). Antibody against C-terminal Abeta selectively elevates plasma Abeta. NeuroReport, 18, 293\u2013296.","journal-title":"NeuroReport"},{"key":"8035_CR42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science, 297, 353\u2013356.","journal-title":"Science"},{"key":"8035_CR43","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/diacare.21.4.518","volume":"21","author":"MI Harris","year":"1998","unstructured":"Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., et al. (1998). Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988\u20131994. Diabetes Care, 21, 518\u2013524.","journal-title":"Diabetes Care"},{"key":"8035_CR44","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1523\/JNEUROSCI.0664-05.2005","volume":"25","author":"RE Hartman","year":"2005","unstructured":"Hartman, R. E., Izumi, Y., Bales, K. R., Paul, S. M., Wozniak, D. F., & Holtzman, D. M. (2005). Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer\u2019s disease. Journal of Neuroscience, 25, 6213\u20136220.","journal-title":"Journal of Neuroscience"},{"key":"8035_CR45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Muller-Tillmanns, B., et al. (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer\u2019s disease. Neuron, 38, 547\u2013554.","journal-title":"Neuron"},{"key":"8035_CR46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ana.10208","volume":"51","author":"RM Holsinger","year":"2002","unstructured":"Holsinger, R. M., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002). Increased expression of the amyloid precursor beta-secretase in Alzheimer\u2019s disease. Annals of Neurology, 51, 783\u2013786.","journal-title":"Annals of Neurology"},{"key":"8035_CR47","doi-asserted-by":"crossref","first-page":"22908","DOI":"10.1074\/jbc.271.37.22908","volume":"271","author":"N Ida","year":"1996","unstructured":"Ida, N., Hartmann, T., Pantel, J., Schroder, J., Zerfass, R., Forstl, H., et al. (1996). Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. Journal of Biological Chemistry, 271, 22908\u201322914.","journal-title":"Journal of Biological Chemistry"},{"key":"8035_CR48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1602\/neurorx.1.2.226","volume":"1","author":"MC Irizarry","year":"2004","unstructured":"Irizarry, M. C. (2004). Biomarkers of Alzheimer disease in plasma. NeuroRx, 1, 226\u2013234.","journal-title":"NeuroRx"},{"key":"8035_CR49","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/00005072-199709000-00002","volume":"56","author":"MC Irizarry","year":"1997","unstructured":"Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K., & Hyman, B. T. (1997). APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. Journal of Neuropathology and Experimental Neurology, 56, 965\u2013973.","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"8035_CR50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0197-4580(98)00015-3","volume":"19","author":"T Iwatsubo","year":"1998","unstructured":"Iwatsubo, T. (1998). Amyloid beta protein in plasma as a diagnostic marker for Alzheimer\u2019s disease. Neurobiology of Aging, 19, 161\u2013163.","journal-title":"Neurobiology of Aging"},{"key":"8035_CR51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., et al. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease. Nature, 408, 979\u2013982.","journal-title":"Nature"},{"key":"8035_CR52","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9","volume":"45","author":"M Jensen","year":"1999","unstructured":"Jensen, M., Schroder, J., Blomberg, M., Engvall, B., Pantel, J., Ida, N., et al. (1999). Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer\u2019s disease and declines with disease progression. Annals of Neurology, 45, 504\u2013511.","journal-title":"Annals of Neurology"},{"key":"8035_CR53","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/341226a0","volume":"341","author":"CL Joachim","year":"1989","unstructured":"Joachim, C. L., Mori, H., & Selkoe, D. J. (1989). Amyloid beta-protein deposition in tissues other than brain in Alzheimer\u2019s disease. Nature, 341, 226\u2013230.","journal-title":"Nature"},{"key":"8035_CR54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410440108","volume":"44","author":"M Kanai","year":"1998","unstructured":"Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., et al. (1998). Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer\u2019s disease: A study in Japan. Annals of Neurology, 44, 17\u201326.","journal-title":"Annals of Neurology"},{"key":"8035_CR55","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ana.410230206","volume":"23","author":"R Katzman","year":"1988","unstructured":"Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., et al. (1988). Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Annals of Neurology, 23, 138\u2013144.","journal-title":"Annals of Neurology"},{"key":"8035_CR56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","volume":"21","author":"T Kawarabayashi","year":"2001","unstructured":"Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001). Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease. Journal of Neuroscience, 21, 372\u2013381.","journal-title":"Journal of Neuroscience"},{"key":"8035_CR57","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/37.8.2666510","volume":"37","author":"WE Klunk","year":"1989","unstructured":"Klunk, W. E., Pettegrew, J. W., & Abraham, D. J. (1989). Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. Journal of Histochemistry and Cytochemistry, 37, 1273\u20131281.","journal-title":"Journal of Histochemistry and Cytochemistry"},{"key":"8035_CR58","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1212\/WNL.48.3.741","volume":"48","author":"T Kosaka","year":"1997","unstructured":"Kosaka, T., Imagawa, M., Seki, K., Arai, H., Sasaki, H., Tsuji, S., et al. (1997). The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology, 48, 741\u2013745.","journal-title":"Neurology"},{"key":"8035_CR59","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1006\/bbrc.1994.2788","volume":"205","author":"A Koudinov","year":"1994","unstructured":"Koudinov, A., Matsubara, E., Frangione, B., & Ghiso, J. (1994). The soluble form of Alzheimer\u2019s amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochemical and Biophysical Research Communications, 205, 1164\u20131171.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"8035_CR60","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000216274.58185.09","volume":"66","author":"JJ Kulstad","year":"2006","unstructured":"Kulstad, J. J., Green, P. S., Cook, D. G., Watson, G. S., Reger, M. A., Baker, L. D., et al. (2006). Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology, 66, 1506\u20131510.","journal-title":"Neurology"},{"key":"8035_CR61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1006\/bbrc.1999.0552","volume":"257","author":"YM Kuo","year":"1999","unstructured":"Kuo, Y. M., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., et al. (1999). High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer\u2019s disease. Biochemical and Biophysical Research Communications, 257, 787\u2013791.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"8035_CR62","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1006\/bbrc.2000.2222","volume":"268","author":"YM Kuo","year":"2000","unstructured":"Kuo, Y. M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., et al. (2000a). Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochemical and Biophysical Research Communications, 268, 750\u2013756.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"8035_CR63","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-9440(10)64947-4","volume":"156","author":"YM Kuo","year":"2000","unstructured":"Kuo, Y. M., Kokjohn, T. A., Watson, M. D., Woods, A. S., Cotter, R. J., Sue, L. I., et al. (2000b). Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. American Journal of Pathology, 156, 797\u2013805.","journal-title":"American Journal of Pathology"},{"key":"8035_CR64","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","volume":"25","author":"FM Laird","year":"2005","unstructured":"Laird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., et al. (2005). BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. Journal of Neuroscience, 25, 11693\u201311709.","journal-title":"Journal of Neuroscience"},{"key":"8035_CR65","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., et al. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America, 95, 6448\u20136453.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"8035_CR66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0969-9961(03)00044-5","volume":"14","author":"CA Lemere","year":"2003","unstructured":"Lemere, C. A., Spooner, E. T., LaFrancois, J., Malester, B., Mori, C., Leverone, J. F., et al. (2003). Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiology of Disease, 14, 10\u201318.","journal-title":"Neurobiology of Disease"},{"key":"8035_CR67","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","volume":"440","author":"S Lesne","year":"2006","unstructured":"Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., et al. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 440, 352\u2013357.","journal-title":"Nature"},{"key":"8035_CR68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1172\/JCI25410","volume":"116","author":"Y Levites","year":"2006","unstructured":"Levites, Y., Das, P., Price, R. W., Rochette, M. J., Kostura, L. A., McGowan, E. M., et al. (2006). Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. Journal of Clinical Investigation, 116, 193\u2013201.","journal-title":"Journal of Clinical Investigation"},{"key":"8035_CR69","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levy-Lahad","year":"1995","unstructured":"Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., et al. (1995). Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science, 269, 973\u2013977.","journal-title":"Science"},{"key":"8035_CR70","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., et al. (1999). Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. American Journal of Pathology, 155, 853\u2013862.","journal-title":"American Journal of Pathology"},{"key":"8035_CR71","doi-asserted-by":"crossref","unstructured":"Maezawa, I., Hong, H. S., Liu, R., Wu, C. Y., Cheng, R. H., Kung, M. P., et al. (2008). Congo red and thioflavin-T analogs detect Abeta oligomers. Journal of Neurochemistry, 107, 457\u2013468.","DOI":"10.1111\/j.1471-4159.2007.04972.x"},{"key":"8035_CR72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/1531-8249(199904)45:4<537::AID-ANA20>3.0.CO;2-2","volume":"45","author":"E Matsubara","year":"1999","unstructured":"Matsubara, E., Ghiso, J., Frangione, B., Amari, M., Tomidokoro, Y., Ikeda, Y., et al. (1999). Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer\u2019s disease and Down\u2019s syndrome. Annals of Neurology, 45, 537\u2013541.","journal-title":"Annals of Neurology"},{"key":"8035_CR73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000100019","volume":"23","author":"Y Matsumoto","year":"2007","unstructured":"Matsumoto, Y., Yanase, D., Noguchi-Shinohara, M., Ono, K., Yoshita, M., & Yamada, M. (2007). Blood\u2013brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood\u2013brain barrier in Alzheimer\u2019s disease. Dementia and Geriatric Cognitive Disorders, 23, 241\u2013245.","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"8035_CR74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1523\/JNEUROSCI.23-01-00029.2003","volume":"23","author":"Y Matsuoka","year":"2003","unstructured":"Matsuoka, Y., Saito, M., LaFrancois, J., Saito, M., Gaynor, K., Olm, V., et al. (2003). Novel therapeutic approach for the treatment of Alzheimer\u2019s disease by peripheral administration of agents with an affinity to beta-amyloid. Journal of Neuroscience, 23, 29\u201333.","journal-title":"Journal of Neuroscience"},{"key":"8035_CR75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/1567205053585774","volume":"2","author":"Y Matsuoka","year":"2005","unstructured":"Matsuoka, Y., Shao, L., Debnath, M., Lafrancois, J., Becker, A., Gray, A., et al. (2005). An Abeta sequestration approach using non-antibody Abeta binding agents. Current Alzheimer Research, 2, 265\u2013268.","journal-title":"Curr Alzheimer Res"},{"key":"8035_CR76","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","volume":"61","author":"R Mayeux","year":"2003","unstructured":"Mayeux, R., Honig, L. S., Tang, M. X., Manly, J., Stern, Y., Schupf, N., et al. (2003). Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: Relation to age, mortality, and risk. Neurology, 61, 1185\u20131190.","journal-title":"Neurology"},{"key":"8035_CR77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A","volume":"46","author":"R Mayeux","year":"1999","unstructured":"Mayeux, R., Tang, M. X., Jacobs, D. M., Manly, J., Bell, K., Merchant, C., et al. (1999). Plasma amyloid beta-peptide 1-42 and incipient Alzheimer\u2019s disease. Annals of Neurology, 46, 412\u2013416.","journal-title":"Annals of Neurology"},{"key":"8035_CR78","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., et al. (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Annals of Neurology, 46, 860\u2013866.","journal-title":"Annals of Neurology"},{"key":"8035_CR79","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta, P. D., Pirttila, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000). Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Archives of Neurology, 57, 100\u2013105.","journal-title":"Archives of Neurology"},{"key":"8035_CR80","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0304-3940(01)01754-2","volume":"304","author":"PD Mehta","year":"2001","unstructured":"Mehta, P. D., Pirttila, T., Patrick, B. A., Barshatzky, M., & Mehta, S. P. (2001). Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neuroscience Letters, 304, 102\u2013106.","journal-title":"Neuroscience Letters"},{"key":"8035_CR81","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. Nature, 408, 982\u2013985.","journal-title":"Nature"},{"key":"8035_CR82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/JMN:17:2:101","volume":"17","author":"JC Morris","year":"2001","unstructured":"Morris, J. C., & Price, A. L. (2001). Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer\u2019s disease. Journal of Molecular Neuroscience, 17, 101\u2013118.","journal-title":"Journal of Molecular Neuroscience"},{"key":"8035_CR83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","volume":"1","author":"SG Mueller","year":"2005","unstructured":"Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., et al. (2005). Ways toward an early diagnosis in Alzheimer\u2019s disease: The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Alzheimers and Dementia, 1, 55\u201366.","journal-title":"Alzheimers Dement"},{"key":"8035_CR84","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1073\/pnas.91.18.8378","volume":"91","author":"J Naslund","year":"1994","unstructured":"Naslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., et al. (1994). Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proceedings of the National Academy of Sciences of the United States of America, 91, 8378\u20138382.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"8035_CR85","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00019442-200211000-00005","volume":"10","author":"J Neugroschl","year":"2002","unstructured":"Neugroschl, J., & Davis, K. L. (2002). Biological markers in Alzheimer disease. American Journal of Geriatric Psychiatry, 10, 660\u2013677.","journal-title":"Am J Geriatr Psychiatry"},{"key":"8035_CR86","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0898-6568(99)00025-X","volume":"11","author":"FH Nystrom","year":"1999","unstructured":"Nystrom, F. H., & Quon, M. J. (1999). Insulin signalling: Metabolic pathways and mechanisms for specificity. Cellular Signalling, 11, 563\u2013574.","journal-title":"Cellular Signalling"},{"key":"8035_CR87","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1523\/JNEUROSCI.3291-05.2006","volume":"26","author":"JH Park","year":"2006","unstructured":"Park, J. H., Gimbel, D. A., GrandPre, T., Lee, J. K., Kim, J. E., Li, W., et al. (2006a). Alzheimer precursor protein interaction with the Nogo\u201366 receptor reduces amyloid-beta plaque deposition. Journal of Neuroscience, 26, 1386\u20131395.","journal-title":"Journal of Neuroscience"},{"key":"8035_CR88","doi-asserted-by":"crossref","first-page":"13279","DOI":"10.1523\/JNEUROSCI.4504-06.2006","volume":"26","author":"JH Park","year":"2006","unstructured":"Park, J. H., Widi, G. A., Gimbel, D. A., Harel, N. Y., Lee, D. H., & Strittmatter, S. M. (2006b). Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer\u2019s transgenic mice. Journal of Neuroscience, 26, 13279\u201313286.","journal-title":"Journal of Neuroscience"},{"key":"8035_CR89","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.neurobiolaging.2006.03.004","volume":"27","author":"M Pesaresi","year":"2006","unstructured":"Pesaresi, M., Lovati, C., Bertora, P., Mailland, E., Galimberti, D., Scarpini, E., et al. (2006). Plasma levels of beta-amyloid (1-42) in Alzheimer\u2019s disease and mild cognitive impairment. Neurobiology of Aging, 27, 904\u2013905.","journal-title":"Neurobiology of Aging"},{"key":"8035_CR90","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev.neuro.21.1.479","volume":"21","author":"DL Price","year":"1998","unstructured":"Price, D. L., & Sisodia, S. S. (1998). Mutant genes in familial Alzheimer\u2019s disease and transgenic models. Annual Review of Neuroscience, 21, 479\u2013505.","journal-title":"Annual Review of Neuroscience"},{"key":"8035_CR91","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price, J. L., & Morris, J. C. (1999). Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Annals of Neurology, 45, 358\u2013368.","journal-title":"Annals of Neurology"},{"key":"8035_CR92","doi-asserted-by":"crossref","first-page":"32730","DOI":"10.1074\/jbc.273.49.32730","volume":"273","author":"WQ Qiu","year":"1998","unstructured":"Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., et al. (1998). Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. Journal of Biological Chemistry, 273, 32730\u201332738.","journal-title":"Journal of Biological Chemistry"},{"key":"8035_CR93","doi-asserted-by":"crossref","first-page":"23946","DOI":"10.1074\/jbc.272.38.23946","volume":"272","author":"KA Quinn","year":"1997","unstructured":"Quinn, K. A., Grimsley, P. G., Dai, Y. P., Tapner, M., Chesterman, C. N., & Owensby, D. A. (1997). Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. Journal of Biological Chemistry, 272, 23946\u201323951.","journal-title":"Journal of Biological Chemistry"},{"key":"8035_CR94","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., et al. (2007). Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins. Nature Medicine, 13, 1359\u20131362.","journal-title":"Nature Medicine"},{"key":"8035_CR95","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/bies.10236","volume":"25","author":"SR Robinson","year":"2003","unstructured":"Robinson, S. R., Bishop, G. M., & Munch, G. (2003). Alzheimer vaccine: Amyloid-beta on trial. Bioessays, 25, 283\u2013288.","journal-title":"Bioessays"},{"key":"8035_CR96","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","volume":"13","author":"A Sagare","year":"2007","unstructured":"Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., et al. (2007). Clearance of amyloid-beta by circulating lipoprotein receptors. Nature Medicine, 13, 1029\u20131031.","journal-title":"Nature Medicine"},{"key":"8035_CR97","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jnr.490370310","volume":"37","author":"MF Saulino","year":"1994","unstructured":"Saulino, M. F., & Schengrund, C. L. (1994). Differential accumulation of gangliosides by the brains of MPTP-lesioned mice. Journal of Neuroscience Research, 37, 384\u2013391.","journal-title":"Journal of Neuroscience Research"},{"key":"8035_CR98","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., et al. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in\u00a0vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nature Medicine, 2, 864\u2013870.","journal-title":"Nature Medicine"},{"key":"8035_CR99","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1212\/WNL.55.3.370","volume":"55","author":"FA Schmitt","year":"2000","unstructured":"Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000). \u201cPreclinical\u201d AD revisited: Neuropathology of cognitively normal older adults. Neurology, 55, 370\u2013376.","journal-title":"Neurology"},{"key":"8035_CR100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0149-7634(00)00040-3","volume":"24","author":"RJ Schulingkamp","year":"2000","unstructured":"Schulingkamp, R. J., Pagano, T. C., Hung, D., & Raffa, R. B. (2000). Insulin receptors and insulin action in the brain: Review and clinical implications. Neuroscience and Biobehavioral Reviews, 24, 855\u2013872.","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"8035_CR101","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-3-14","volume":"3","author":"TJ Seabrook","year":"2006","unstructured":"Seabrook, T. J., Jiang, L., Thomas, K., & Lemere, C. A. (2006). Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40\/42 in APP-tg mice. J Neuroinflammation, 3, 14.","journal-title":"J Neuroinflammation"},{"key":"8035_CR103","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.275.5300.630","volume":"275","author":"DJ Selkoe","year":"1997","unstructured":"Selkoe, D. J. (1997). Alzheimer\u2019s disease: Genotypes, phenotypes, and treatments. Science, 275, 630\u2013631.","journal-title":"Science"},{"key":"8035_CR104","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0896-6273(01)00475-5","volume":"32","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe, D. J. (2001). Clearing the Brain\u2019s Amyloid Cobwebs. Neuron, 32, 177\u2013180.","journal-title":"Neuron"},{"key":"8035_CR102","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1172\/JCI0216783","volume":"110","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe, D. J. (2002). Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. Journal of Clinical Investigation, 110, 1375\u20131381.","journal-title":"Journal of Clinical Investigation"},{"key":"8035_CR105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature, 375, 754\u2013760.","journal-title":"Nature"},{"key":"8035_CR106","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., et al. (2000). Clearance of Alzheimer\u2019s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood\u2013brain barrier. Journal of Clinical Investigation, 106, 1489\u20131499.","journal-title":"Journal of Clinical Investigation"},{"key":"8035_CR107","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/WNF.0b013e31805b7660","volume":"30","author":"ER Siemers","year":"2007","unstructured":"Siemers, E. R., Dean, R. A., Friedrich, S., Ferguson-Sells, L., Gonzales, C., Farlow, M. R., et al. (2007). Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clinical Neuropharmacology, 30, 317\u2013325.","journal-title":"Clinical Neuropharmacology"},{"key":"8035_CR108","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.WNL.0000198762.41312.E1","volume":"66","author":"ER Siemers","year":"2006","unstructured":"Siemers, E. R., Quinn, J. F., Kaye, J., Farlow, M. R., Porsteinsson, A., Tariot, P., et al. (2006). Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology, 66, 602\u2013604.","journal-title":"Neurology"},{"key":"8035_CR109","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S1474-4422(03)00487-3","volume":"2","author":"GD Silverberg","year":"2003","unstructured":"Silverberg, G. D., Mayo, M., Saul, T., Rubenstein, E., & McGuire, D. (2003). Alzheimer\u2019s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: A hypothesis. Lancet Neurology, 2, 506\u2013511.","journal-title":"Lancet Neurol"},{"key":"8035_CR110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/990114","volume":"402","author":"S Sinha","year":"1999","unstructured":"Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., et al. (1999). Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature, 402, 537\u2013540.","journal-title":"Nature"},{"key":"8035_CR111","first-page":"17036","volume":"276","author":"DM Skovronsky","year":"2001","unstructured":"Skovronsky, D. M., Lee, V. M., & Pratico, D. (2001). Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. Journal of Biological Chemistry, 276, 17036\u201317043.","journal-title":"Role of cyclooxygenase and protein kinase C. J Biol Chem"},{"key":"8035_CR112","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchromb.2006.08.003","volume":"846","author":"JR Slemmon","year":"2007","unstructured":"Slemmon, J. R., Painter, C. L., Nadanaciva, S., Catana, F., Cook, A., Motter, R., et al. (2007). Distribution of Abeta peptide in whole blood. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 846, 24\u201331.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"8035_CR113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neuron.2006.09.001","volume":"52","author":"SA Small","year":"2006","unstructured":"Small, S. A., & Gandy, S. (2006). Sorting through the cell biology of Alzheimer\u2019s disease: Intracellular pathways to pathogenesis. Neuron, 52, 15\u201331.","journal-title":"Neuron"},{"key":"8035_CR114","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.20524","volume":"58","author":"C Stenh","year":"2005","unstructured":"Stenh, C., Englund, H., Lord, A., Johansson, A. S., Almeida, C. G., Gellerfors, P., et al. (2005). Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Annals of Neurology, 58, 147\u2013150.","journal-title":"Annals of Neurology"},{"key":"8035_CR115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/archneurol.2007.57","volume":"65","author":"J Sundelof","year":"2008","unstructured":"Sundelof, J., Giedraitis, V., Irizarry, M. C., Sundstrom, J., Ingelsson, E., Ronnemaa, E., et al. (2008). Plasma beta Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study. Archives of Neurology, 65, 256\u2013263.","journal-title":"Archives of Neurology"},{"key":"8035_CR116","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","volume":"289","author":"T Sunderland","year":"2003","unstructured":"Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., et al. (2003). Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA, 289, 2094\u20132103.","journal-title":"JAMA"},{"key":"8035_CR117","doi-asserted-by":"crossref","unstructured":"Takata, K., Hirata-Fukae, C., Becker, A. G., Chishiro, S., Gray, A. J., Nishitomi, K., et al. (2007). Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. European Journal of Neuroscience, 26, 2458\u20132468.","DOI":"10.1111\/j.1460-9568.2007.05852.x"},{"key":"8035_CR118","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s11095-006-0208-7","volume":"23","author":"C Tamaki","year":"2006","unstructured":"Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., et al. (2006). Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharmaceutical Research, 23, 1407\u20131416.","journal-title":"Pharmaceutical Research"},{"key":"8035_CR119","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/mol.107.036913","volume":"72","author":"C Tamaki","year":"2007","unstructured":"Tamaki, C., Ohtsuki, S., & Terasaki, T. (2007). Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1-40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Molecular Pharmacology, 72, 850\u2013855.","journal-title":"Molecular Pharmacology"},{"key":"8035_CR120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-510X(96)00143-8","volume":"141","author":"A Tamaoka","year":"1996","unstructured":"Tamaoka, A., Fukushima, T., Sawamura, N., Ishikawa, K., Oguni, E., Komatsuzaki, Y., et al. (1996). Amyloid beta protein in plasma from patients with sporadic Alzheimer\u2019s disease. Journal of the Neurological Sciences, 141, 65\u201368.","journal-title":"Journal of the Neurological Sciences"},{"key":"8035_CR121","first-page":"605","volume":"43","author":"RE Tanzi","year":"2004","unstructured":"Tanzi, R. E., Moir, R. D., & Wagner, S. L. (2004). Clearance of Alzheimer\u2019s Abeta peptide: The many roads to perdition. Neuron, 43, 605\u2013608.","journal-title":"Neuron"},{"key":"8035_CR122","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.410410220","volume":"41","author":"T Tokuda","year":"1997","unstructured":"Tokuda, T., Fukushima, T., Ikeda, S., Sekijima, Y., Shoji, S., Yanagisawa, N., et al. (1997). Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down\u2019s syndrome. Annals of Neurology, 41, 271\u2013273.","journal-title":"Annals of Neurology"},{"key":"8035_CR123","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0197-4580(96)00028-0","volume":"17","author":"JC Troncoso","year":"1996","unstructured":"Troncoso, J. C., Martin, L. J., Dal Forno, G., & Kawas, C. H. (1996). Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiology of Aging, 17, 365\u2013371.","journal-title":"Neurobiology of Aging"},{"key":"8035_CR124","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","volume":"5","author":"M Oijen van","year":"2006","unstructured":"van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006). Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurology, 5, 655\u2013660.","journal-title":"Lancet Neurol"},{"key":"8035_CR125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/13506120009146438","volume":"7","author":"H Vanderstichele","year":"2000","unstructured":"Vanderstichele, H., Van Kerschaver, E., Hesse, C., Davidsson, P., Buyse, M. A., Andreasen, N., et al. (2000). Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid, 7, 245\u2013258.","journal-title":"Amyloid"},{"key":"8035_CR126","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., et al. (1999). Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286, 735\u2013741.","journal-title":"Science"},{"key":"8035_CR127","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in\u00a0vivo. Nature, 416, 535\u2013539.","journal-title":"Nature"},{"key":"8035_CR128","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1212\/01.WNL.0000065916.25128.25","volume":"60","author":"GS Watson","year":"2003","unstructured":"Watson, G. S., Peskind, E. R., Asthana, S., Purganan, K., Wait, C., Chapman, D., et al. (2003). Insulin increases CSF Abeta42 levels in normal older adults. Neurology, 60, 1899\u20131903.","journal-title":"Neurology"},{"key":"8035_CR129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nm0103-3","volume":"9","author":"LB Yang","year":"2003","unstructured":"Yang, L. B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X. L., et al. (2003). Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nature Medicine, 9, 3\u20134.","journal-title":"Nature Medicine"},{"key":"8035_CR130","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.4049\/jimmunol.177.4.2662","volume":"177","author":"E Zamora","year":"2006","unstructured":"Zamora, E., Handisurya, A., Shafti-Keramat, S., Borchelt, D., Rudow, G., Conant, K., et al. (2006). Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. Journal of Immunology, 177, 2662\u20132670.","journal-title":"Journal of Immunology"}],"container-title":["NeuroMolecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-008-8035-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12017-008-8035-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-008-8035-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T06:39:40Z","timestamp":1709015980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12017-008-8035-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,10]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["8035"],"URL":"https:\/\/doi.org\/10.1007\/s12017-008-8035-0","relation":{},"ISSN":["1535-1084","1559-1174"],"issn-type":[{"value":"1535-1084","type":"print"},{"value":"1559-1174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,10]]}}}